



Provincial Health Services Authority

MEDICAL ALERT

NAME _____

is being treated with
ivosidenib:

DIFFERENTIATION SYNDROME RISK

**ALWAYS CARRY THIS CARD AND SHOW TO ALL
PHYSICIANS INCLUDING ANESTHETISTS**

DIFFERENTIATION SYNDROME may occur up to 33 days after starting ivosidenib and may be life-threatening if untreated. Symptoms include non-infectious leukocytosis, peripheral or pulmonary edema, pyrexia, dyspnea, pleural or pericardial effusion, hypotension, rash, fluid overload, tumor lysis syndrome and increased creatinine. If suspected, initiate corticosteroid therapy and hemodynamic monitoring.

FOR MORE INFORMATION:

- BC Cancer - Abbotsford604-851-4710
- BC Cancer - Kelowna250-712-3900
- BC Cancer - Prince George.....250-645-7300
- BC Cancer - Surrey604-930-4055
- BC Cancer - Vancouver.....604-877-6000
- BC Cancer - Victoria.....250-519-5500
- VGH Leukemia/BMT Program..... 604-875-4111

www.bccancer.bc.ca/cdm

Rev. 1 Jul 2026